Twist Bioscience Corp (TWST) Senior Vice President, Chief Legal Officer & Corporate Secretary Dennis Cho sold 348 shares of common stock on September 21, 2026, at $165.4910 per share. The sale covered tax withholding obligations related to vesting of Restricted Stock Units and was required under the issuer’s equity-plan election, rather than a discretionary trade. Cho reported 73,303 shares held directly after the sale. No Rule 10b5-1 plan is reported.
At Twist Bioscience, SVP of Human Resources Paula Green sold 294 common shares at $165.4910 per share on September 21, 2026, leaving her with 116,720 directly held shares. The sale covered tax withholding obligations connected with vesting of Restricted Stock Units. The issuer's equity incentive plan required the “sell to cover” transaction, which the footnote says was not discretionary. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp CEO and director Emily M. Leproust sold 1,687 common shares on September 21, 2026, at $165.4910 per share. The sale was a mandatory “sell to cover” transaction for tax withholding in connection with Restricted Stock Unit vesting, not a discretionary trade; no Rule 10b5-1 plan is reported. She directly held 618,902 common shares after the sale. The filing also lists options covering 131,290 shares at an exercise price of $23.3300 and 64,950 shares at $67.8500.
Twist Bioscience Corp (TWST) reported that Emily M. Leproust plans to sell 1,687 shares of common stock through Fidelity Brokerage Services LLC under Rule 144. The planned sale has an aggregate market value of $279,183.99, with 62,707,424 shares outstanding as of the notice.
In the prior three months, Leproust reported multiple Rule 144 sales of Twist Bioscience common stock, including 356,546 shares for $56,330,878.38 on September 17, 2026. The filing notes that the sale includes shares needed to cover a tax obligation from a vested equity award.
Twist Bioscience Corp (TWST) received a notice under Rule 144 for proposed sales of its common stock by officer Paula Green. The current notice covers 294 shares to be sold through Fidelity Brokerage Services, with an aggregate market value of $48,654.47, and references 62,707,424 shares of common stock outstanding. The filing notes that the sale includes shares to cover a tax obligation from the settlement of a vested equity award.
Twist Bioscience Corp (TWST) has a notice under Rule 144 for planned sales of common stock by officer Dennis H. Cho. The filing covers 348 shares held at Fidelity Brokerage Services LLC, valued at $57,591.01 as of September 21, 2026, acquired through restricted stock vesting on September 18, 2026 as compensation from the issuer. The remark states that the planned sale includes shares to cover a tax obligation from the settlement of a vested equity award distribution and lists multiple prior common stock sales by Cho during the preceding three months.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust exercised employee stock options and sold common shares on September 17, 2026 under a Rule 10b5-1 trading plan adopted on June 15, 2026.
She exercised options for 208,708 shares of Common Stock, including 75,439 shares at an exercise price of $8.82 per share expiring September 28, 2027 and 133,269 shares at an exercise price of $26.66 per share expiring November 18, 2028. On the same date she sold 356,546 shares of Common Stock in multiple open-market transactions at weighted average prices per share ranging from approximately $150.77 to $163.60.
Following these transactions, she continues to hold employee stock options directly, including options linked to 131,290 underlying shares at an exercise price of $23.33 per share expiring October 23, 2029 and options linked to 64,950 underlying shares at an exercise price of $67.85 per share expiring August 31, 2030, as reported.
Twist Bioscience Corp (TWST) security holder Emily M. Leproust has provided notice under Rule 144 of a proposed sale of up to 295,037 shares of common stock, with an aggregate market value of $44,677,452.91, expected around September 17, 2026 on NASDAQ.
The notice lists these shares as having been acquired through various restricted stock vestings, an ESPP purchase, and a stock option exercise for 208,708 shares. Twist Bioscience Corp reports 62,707,424 common shares outstanding as of September 17, 2026; this is a baseline figure, not the amount being sold.
Twist Bioscience Corp (TWST) has a notice of proposed sale of restricted and other common shares under Rule 144 by security holder Emily M. Leproust. The filing indicates a proposed sale of 61,509 shares of common stock, with an aggregate market value of $9,314,307.87, and notes 62,707,424 shares of common stock outstanding. The notice also lists prior issuances to Leproust through restricted stock vesting and Employee Stock Purchase Plan purchases, as well as multiple common stock sales in recent months.
Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 412 shares of common stock on September 8, 2026 at $122.62 per share. According to the company’s disclosure, these shares were sold solely to cover tax withholding upon vesting of Restricted Stock Units, and were not discretionary trades. After this transaction, Cho directly held 73,651 shares of Twist Bioscience common stock. No Rule 10b5-1 trading plan is reported for this transaction.